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Endothelial permeability in uremia. The risk of cardiovascular THE ENDOTHELIUM
disease is significantly higher in patients with long-term uremia Structure (Full review)than in otherwise healthy adults. In addition, the risk is greater
than what would be predicted from classic vascular risk factors. A monolayer of endothelial cells, covering glycocalyx
This is true even before patients proceed to dialysis. Although and underlying basement membrane constitute the endo-
the reasons for this accelerated vascular disease are unknown, thelium [6]. Transport of agents from lumen to the sub-transendothelial transport of lipids and other macromolecules
endothelium depends on the molecules’ ability to traversein both large vessels and the microcirculation has been impli-
all three barriers. Although many texts represent thecated in the generation of cardiovascular disease. Furthermore,
endothelial cell dysfunction is widely accepted as a cardinal endothelium as a cobblestone-pattern of cells, endothe-
feature of both modest and dialysis-dependent uremia, and is lial cells are in truth attenuated principally in the direc-
regarded as a critical step in the initiation of this aggressive tion of flow, often overlap each other, and on electron
pathology. This overview considers the severity of the clinical
microscopic examination are connected with each otherproblem, the nature of the vascular endothelium, microvascular
via intercellular junctions.permeability (and the measurement thereof) as a functional
property of the endothelium, and the in vitro and in vivo evi-
Function (Full review)dence for endothelial dysfunction in uremia.
The endothelium is an active dynamic organ that ful-
fills many crucial roles [7]. First, it is a physical barrier,
ultra-structurally defining the components of the vessel
wall and the contents of the vessel lumen. Second, thisTHE CLINICAL PROBLEM
barrier affords movement of some small solutes (O2, glu-Uremia is associated with increased vascular risk and
cose, etc.), in preference to large molecules (e.g., albumin),
premature death [1] in both dialysis- and nondialysis- and is, therefore, involved in tissue autoregulation. Third,
dependent patients [2], and may be up to one hundred- the endothelium affords an antithrombotic environment.
fold in certain patient groups [2]. Uremic vascular disease Fourth, the endothelium mediates vasoactivity. Finally, the
is macro- and microvascular, and is associated with re- endothelium mediates adherence of platelets and white
duced arterial compliance [3]. Classic risk factors (blood blood cells to the vessel wall during injury and inflamma-
pressure, dyslipidemia, salt intake, smoking) underesti- tion, respectively. In summary, the endothelium mediates
mate the cardiovascular risk apparent in uremia [4]. Less and integrates signals that arise from the vessel lumen,
conventional risk factors have therefore received in- with targets in the vessel wall or adjacent tissue, and vice
creased attention (Table 1). Despite the controversy over versa [8]. Furthermore, the endothelium is not a homoge-
the role of these potential factors, it is clear that the neous population of cells. Endothelial cell phenotypes
increased cardiovascular risk begins when the renal im- are determined by their embryologic origin (macro- or
pairment is modest [1]. In line with the “response to microvascular) and local environmental factors [8]. In
endothelial damage hypothesis,” it has been speculated such a way, specialized functions of the endothelium can
that the aggressive nature of uremic vascular disease be anatomically site-specific (e.g., in the glomerulus).
relates to persistent and chronic endothelial damage and
impaired function. Furthermore, it is held that endothe-
PERMEABILITYlial dysfunction is directly linked to the uremia state, and
Lipidsthat dysfunction at a specific site within the vasculature
precedes the development of atherosclerotic plaque [5]. Fully lipid-soluble molecules (including gases) traverse
the endothelium by free diffusion. The movement of lipo-
proteins and glycolipids is more restricted by size and hydro-Key words: capillary permeability, kidney disease, vascular endothe-
lium, microvasculature, atherosclerosis. phobicity, and indeed some species (e.g., low-density lipo-
protein [LDL]) cross the endothelium by transcytosis [9]. 2003 by the International Society of Nephrology
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Table 1. Potential nonclassical vascular risk factors in uremia Permeability of continuous capillaries to small hydro-
philic molecules is greater (e.g., for insulin 1  5  106Additional oxygen demand secondary to left ventricular hypertrophy
Stiffening of the arterial tree cm · s1). Fenestrated capillaries (synovium, kidney) are
Anemia associated with high fluid turnover. In most fenestrationsRecurrent/chronic salt and water overload
a cartwheel spoke-type diaphragm made of the proteinArteriovenous fistulae
Microalbuminuria, assuming this is a reflection of a generalized increase PV-1 is found, resulting in a small “pore diameter,” but
in endothelial permeability very short pathlength. This results in very high hydraulicAccumulation of potential endothelial toxins (e.g., homocysteine, hyper-
conductivity and diffusive permeability (Lp 4–20  107phosphatemia, and acute-phase reactants/cytokines from chronic
inflammatory processes), leading to hypoalbuminemia (the MIA cm · s1 cm H2O1, Ps for insulin  50  106 cm ·
syndrome) s1), but a reflection coefficient to albumin that is similarAccumulation of ADMA
to continuous capillaries (0.8). Nondiaphragmatic fe-Decreased antioxidant defense/increased oxidative stress
Accumulation of AGEs nestrated capillaries are found in the glomerulus, but the
Accumulation of other nonenzymatic biochemical modifications of reflection coefficient of the endothelium, independentcarbohydrates and lipids, such as ALEs
of the podocytes, has not been determined.
Abbreviations are: MIA, malnutrition, inflammation and hypoalbuminemia;
Other pathways may predominate in particular situa-ADMA, asymmetric dimethylarginine; AGEs, advanced glycation end products;
ALEs, advanced lipoxidation end products. tions or in response to given stimuli; for example, vascu-
lar endothelial growth factor (VEGF) stimulates the pro-
duction of large trans-endothelial cell holes [10].
Water and small hydrophilic solutes Macromolecules
Permeability has a strict definition: the rate of trans- The preferential endothelial perm-selectivity to small
barrier movement of a substance per unit time (volume- molecules confers osmotic potential to the luminal con-
cm3 or mass-mg or mmol, per unit time-s), per unit area tents. The ability of the endothelium to resist the passage
(of barrier) (cm2) per unit driving force (pressure differ- of large molecules is called the oncotic reflection coefficient
ence for water, concentration gradient for solutes). There and, in effect, is an assessment of endothelial pore size.
are strict units for permeability; for example, hydraulic
conductivity (permeability to water) has units of cm3/s/
MEASUREMENT OFcm2/cm H2O  cm · s1 · cm H2O1, while oncotic reflec-
HYDRAULIC CONDUCTIVITYtion coefficient (a ratio) is dimensionless and has no
units. The trans-endothelial movement of fluid within As stated above, if pressure and/or surface area are
the microcirculation is summarized by the Starling equa- unknown or immeasurable, then permeability cannot be
tion: Jv/ALp[(Pc  Pi)  (c  I)], in which Jv/A is assessed. One widely used assay for measuring perme-
the trans-endothelial fluid flux, Lp is hydraulic conductiv- ability is the Miles Assay [11]. Pressure and area are
ity, the bracketed term defines the pressure across the immeasurable in this assay, so the technique cannot as-
vessel wall, where Pc and Pi are the capillary and intersti- sess permeability. It is not possible to assess permeability
tial pressures, respectively,  is the oncotic reflection co- in vivo in humans. However, the Landis-Michel micro-
efficient, and c and I are the capillary and interstitial occlusion technique does allow in vivo measurements in
oncotic pressures, respectively. Endothelial cells may ex- animals [12].
press diaphragmatic and nondiaphragmatic fenestrations,
Calculation of hydraulic conductivity (Lp) andtranscellular holes, vesiculo-vacuolar organelles, and inter-
oncotic reflection coefficient () using thecellular clefts and gaps. The strict contribution of these
Landis-Michel techniquedifferent “pores” to water flux is incompletely defined.
Under normal circumstances in normal vessels in most Consider a capillary (Fig. 1A) cannulated on the left
capillary beds, fluid exchange is defined by intercellular side by a micropipette containing a low haematocrit fluid
clefts, and/or fenestrations. The permeability is deter- under known pressure. Red blood cells will move from
mined by apposition of the endothelial cells, both by the left to right. Occlusion of the capillary stops fluid, and,
number of the tight junctions between the cells (the hence, red blood cell movement out of the vessel, but
“pore” diameter), the degree of overlap of the tight transmural fluid loss distal to the red blood cells causes
junctions and the cells (the “pore” pathlength), and the the red blood cells to move toward the occlusion. Trans-
number and permeability of the fenestrations. Continu- endothelial water flux (Jv/A) can be calculated from the
ous capillaries (skin, skeletal muscle, CNS) have no fen- red blood cell velocity (dL/dt) and is given by [(dl/dt) ·r2/
estrations and multiple tight junctions, and a low perme- 2r · l]  (dL/dt) · (r/2L). The flux-pressure relationship
ability to both water (Lp  0.1  2  107 cm · s1 is defined in Figure 1B. Hydraulic conductivity (Lp) - is
cm H2O1) and large molecules (reflection coefficient the gradient of the line. The graph also predicts the
perfusate oncotic pressure (Point A – when flux is zero,0.8–0.99, diffusive permeability 0.1  2  108 cm · s1).
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Fig. 1. The Landis-Michel micro-occlusion
technique for the in vivo measurement of per-
meability. (A) Jv/A  transendothlial fluid
flux, P, pressure; L, distance to block site; r,
radius of capillary (see text). (B) The transen-
dothelial flux-pressure relationship is defined
by the calculation of Jv/A at a variety of pres-
sures. Lp, hydraulic conductivity; point A pre-
dicts the effective perfusate oncotic pressure
difference, and hence, can be used to calculate
the reflection coefficient. (C) Mean  SEM Lp
of frog mesenteric microvessels. Vessels were
perfused with 5% HSA, normal plasma, or
uremic plasma. Permeability was significantly
greater during perfusion with uremic plasma
than with normal plasma or HSA. (D) Mean
SEM  of frog mesenteric microvessels. Ves-
sels were perfused with 5% HSA, normal
plasma, or uremic plasma.  was significantly
lower, and therefore permeability was signifi-
cantly greater during perfusion with uremic
plasma than with normal plasma or HSA.
perfusion pressure  effective oncotic pressure). The Dynamic, functional, and in vivo data
relationship between this predicted oncotic pressure dif- Endothelium-dependent vasodilatation of conduit ar-
ference () and that measured directly via a Hansen teries is reduced in hemodialysis and CAPD patients,
oncometer (H) defines the oncotic reflection coefficient and in nondialysis-dependent uremia, but again, there
[  (/H)] [13]. is no direct link to level of renal function or atherosclero-
sis [15]. Video-microscopy has demonstrated a blunted
endothelial-dependent vasodilatation and capillary re-IN VITRO AND IN VIVO EVIDENCE FOR
cruitment in nondialysis-dependent uremia (abstract;UREMIC ENDOTHELIAL DYSFUNCTION
Hasan KM et al, J Vasc Res 39:Suppl 1, 2002). The onlyDescriptive and in vitro data
in vivo evidence that uremic plasma may directly affect
Structurally, there is reduced basal and maximal cuta-
endothelial cell function was recently published fromneous capillary density in uremia independent of cardio-
our laboratory [19]. Using the Landis-Michel technique,vascular risk factors (abstract; Hasan KM, J Vasc Res 39:
we have studied plasma from nondialysis-requiring uremicSuppl 1, 2002). Surrogate markers for endothelial cell
patients (Cockcroft & Gault 10-32mL/min) and matchedinjury, including high plasma levels of endothelial cell-
controls. Cannulated mesenteric capillaries of pithed frogsderived glycoproteins (vWF, t-PA, u-PA, soluble thrombo-
were perfused with 5% human serum albumin (HSA),modulin, endothelin-1, ICAM-1, VCAM-1, and MCP-1)
normal, or uremic human plasma. Vessels perfused withhave been identified in uremia, in addition to an impaired
HSA or normal plasma demonstrated no alteration inrelease of such compounds in response to vasopressin [14],
hydraulic conductivity or reflection coefficient. Uremicalthough such circulating levels have no relationship with
plasma, however, significantly increased hydraulic con-degree of uremia or vascular disease [15]. In addition,
ductivity and reduced oncotic reflection coefficient (Fig.circulating levels of other molecules known to affect endo-
1 C and D, respectively). These data add credence tothelial function are increased in uremia (e.g., VEGF, a
the view that vascular endothelial function becomes ab-potent mediator of angiogenesis and increased microvascu-
normal upon exposure to the constituents of uremiclar permeability) [16]. Although it is not known whether
plasma. We therefore hypothesize that in humans, athe latter study identified high levels of circulating stimu-
chronic alteration in endothelial permeability may belatory pro-angiogenic or inhibitory anti-angiogenic VEGF
an important pathogenic mechanism that underlies theisoforms [17], it is known that atherogenesis is angiog-
premature vascular disease seen in this clinical group; aenesis- and VEGF-dependent [18]. Additional in vivo
chronic increase in endothelial permeability may be atstudies [19] confirm that the uremic milieu may be pro-
atherogenic. least one process by which risk factors act in uremia,
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